High-Altitude lung patients breathe better at lower elevations, study finds
NCT ID NCT06489717
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 24 people with high-altitude pulmonary hypertension who live above 2500 meters. Researchers measured their sleep breathing at 3200 meters and again after moving to 760 meters. The goal was to see if lower altitude improves oxygen levels and reduces breathing pauses during sleep.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could show that moving to lower altitudes improves sleep breathing for people with high-altitude pulmonary hypertension.
- What could go wrong
- This is a small, completed observational study with only 24 participants, so results may not apply to everyone. It does not test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
24 people
The number who actually took part.
- Started
-
Jul 2024
- Finished
-
Jul 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Permanently living \>2500 m * HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an altitude of 3200 m * Written informed consent Exclusion Criteria: * Highlanders who cannot follow the study investigations, * Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years. * Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months * Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for High altitude pulmonary hypertension are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aksay Medical Center
Aksay Plateau, Naryn, Kyrgyzstan, Kyrgyzstan
More trials for these conditions
Other studies related to the condition(s) this trial covers.